PLAT and COVID-19: In contrast, tPA activity increased marginally from Day 1 to Day 7 in the TM5614 group (p = 0.06), whereas it did not change in the placebo group, suggesting that TM5614 could have a pro-fibrinolytic effect even in the pro-coagulation environment of COVID-19.